News &amp; Updates

Denosumab proves better than ibandronate as a sequential therapy in women with postmenopausal osteoporosis who have received romosozumab, as the former yields greater improvements in bone mineral density (BMD) with few severe adverse events, according to the results of the VICTOR study.

BMD gains in postmenopausal osteoporosis more favourable with denosumab vs ibandronate

Triheptanoin for seizure reduction disappoints in patients with Glut1DS

Treatment with triheptanoin does not lead to a significant reduction in the frequency of seizures associated with glucose transporter 1 deficiency syndrome (Glut1DS), as shown in a study.

Triheptanoin for seizure reduction disappoints in patients with Glut1DS

Are biologic agents of any help in treating mucous membrane pemphigoid?

10 Jul 2022

Biologic treatments are effective in the treatment of mucous membrane pemphigoid (MMP), with a good safety profile, except for rituximab, a study has found. However, randomized clinical trials with long-term follow-up are warranted to confirm the safety and efficacy of these agents in MMP patients.

Are biologic agents of any help in treating mucous membrane pemphigoid?

10 Jul 2022

Sabizabulin for metastatic castration-resistant prostate cancer clears phase early trial

10 Jul 2022

The oral cytoskeleton disruptor sabizabulin shows antitumour activity in men with metastatic castration-resistant prostate cancer, while having a favourable safety profile, as shown in the results of a phase Ib/II trial.

Sabizabulin for metastatic castration-resistant prostate cancer clears phase early trial

10 Jul 2022

Delgocitinib ointment beneficial in chronic hand eczema

The pan-Janus kinase (JAK) inhibitor delgocitinib in an ointment formulation is well tolerated and demonstrates a dose-response effect in the treatment of patients with chronic hand eczema, according to the results of a phase IIb trial.

Delgocitinib ointment beneficial in chronic hand eczema

Dutasteride shows promise for chronic prostatitis

Dutasteride treatment leads to a significant reduction in chronic prostatitis symptom scores in patients with category IIIB disease, a new study has found.

Dutasteride shows promise for chronic prostatitis

09 Jul 2022

Quizartinib bounces back, doubles OS in FLT3-ITD-positive AML

09 Jul 2022 by

The oral FLT3 inhibitor quizartinib more than doubled overall survival (OS) when added to first-line chemotherapy in patients with newly diagnosed FLT3-ITD*-positive acute myeloid leukaemia (AML) in the phase III QuANTUM-First** trial

Quizartinib bounces back, doubles OS in FLT3-ITD-positive AML

Triplet regimen works against triple-negative breast cancer

Treatment with a novel combination of famitinib, camrelizumab, and nab-paclitaxel appears safe and effective in patients with advanced immunomodulatory triple-negative breast cancer (TNBC), as shown in the results of the phase II FUTURE-C-Plus trial.

Triplet regimen works against triple-negative breast cancer

08 Jul 2022

Medication history assessment by pharmacists vital in detecting errors

Evaluation of medication history by pharmacists has allowed the detection of medication errors, mostly medication omissions, reports a recent study.

Medication history assessment by pharmacists vital in detecting errors

Peripheral intravenous norepinephrine safe at low doses for <24 hours

08 Jul 2022 by

It is safe to administer norepinephrine through a peripheral intravenous catheter (PIV) at low doses for <24 hours using a protocol, suggests a study. Preventing the unnecessary insertion of central venous catheter (CVC) helps minimize the risk of central line complications, thus improving patient morbidity.

Peripheral intravenous norepinephrine safe at low doses for <24 hours